Twist Bioscience (NASDAQ:TWST) SVP Sells $313,015.56 in Stock

Key Points

• Paula Green, SVP of Twist Bioscience, sold $313,015.56 worth of stock on October 6th, decreasing her ownership by 7.82%.
• Twist Bioscience's stock is currently trading at $32.79, reflecting a 5.4% increase with a market cap of $1.98 billion.
• Recent analyst ratings for Twist Bioscience include a price target reduction by Evercore ISI from $46.00 to $42.00, maintaining an "outperform" rating.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) SVP Paula Green sold 9,724 shares of the firm's stock in a transaction on Monday, October 6th. The stock was sold at an average price of $32.19, for a total value of $313,015.56. Following the transaction, the senior vice president directly owned 114,678 shares of the company's stock, valued at approximately $3,691,484.82. This represents a 7.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Paula Green also recently made the following trade(s):

• On Monday, September 22nd, Paula Green sold 295 shares of Twist Bioscience stock. The stock was sold at an average price of $27.56, for a total value of $8,130.20.
• On Monday, September 8th, Paula Green sold 892 shares of Twist Bioscience stock. The stock was sold at an average price of $25.76, for a total value of $22,977.92.

Twist Bioscience Trading Up 5.4%

Shares of TWST stock traded up $1.67 during mid-day trading on Wednesday, hitting $32.79. The company's stock had a trading volume of 2,438,969 shares, compared to its average volume of 1,273,207. The company's fifty day simple moving average is $27.76 and its 200-day simple moving average is $32.84. Twist Bioscience Corporation has a 52 week low of $24.07 and a 52 week high of $55.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. The company has a market cap of $1.98 billion, a PE ratio of -22.61 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%.The firm had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on TWST. Evercore ISI lowered their price objective on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating for the company in a research report on Tuesday. Cowen restated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Barclays reduced their target price on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating for the company in a research note on Thursday, October 2nd. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Twist Bioscience in a research note on Wednesday. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $48.50.

Hedge Funds Weigh In On Twist Bioscience

A number of hedge funds have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after buying an additional 1,588,587 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Twist Bioscience by 18.5% in the 1st quarter. Farther Finance Advisors LLC now owns 6,435 shares of the company's stock worth $251,000 after purchasing an additional 1,006 shares during the period. Strs Ohio bought a new stake in shares of Twist Bioscience in the 1st quarter worth approximately $711,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Twist Bioscience in the 1st quarter worth approximately $396,000. Finally, GAMMA Investing LLC raised its holdings in shares of Twist Bioscience by 68.1% in the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock worth $29,000 after purchasing an additional 303 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.